GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (FRA:8EM) » Definitions » Shiller PE Ratio

Editas Medicine (FRA:8EM) Shiller PE Ratio : (As of Dec. 14, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Editas Medicine Shiller PE Ratio Historical Data

The historical data trend for Editas Medicine's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Shiller PE Ratio Chart

Editas Medicine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Editas Medicine Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Editas Medicine's Shiller PE Ratio

For the Biotechnology subindustry, Editas Medicine's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Editas Medicine's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Shiller PE Ratio falls into.



Editas Medicine Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Editas Medicine's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Editas Medicine's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.676/133.0289*133.0289
=-0.676

Current CPI (Sep. 2024) = 133.0289.

Editas Medicine Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.289 99.070 -0.388
201503 -0.322 99.621 -0.430
201506 -2.751 100.684 -3.635
201509 -0.433 100.392 -0.574
201512 -0.327 99.792 -0.436
201603 -0.718 100.470 -0.951
201606 -0.481 101.688 -0.629
201609 -0.526 101.861 -0.687
201612 -1.043 101.863 -1.362
201703 -0.795 102.862 -1.028
201706 -0.579 103.349 -0.745
201709 -0.537 104.136 -0.686
201712 -0.710 104.011 -0.908
201803 -0.543 105.290 -0.686
201806 -0.702 106.317 -0.878
201809 -0.274 106.507 -0.342
201812 -0.457 105.998 -0.574
201903 -0.531 107.251 -0.659
201906 -0.611 108.070 -0.752
201909 -0.599 108.329 -0.736
201912 -0.666 108.420 -0.817
202003 -0.624 108.902 -0.762
202006 -0.382 108.767 -0.467
202009 0.102 109.815 0.124
202012 -0.822 109.897 -0.995
202103 -0.722 111.754 -0.859
202106 -0.672 114.631 -0.780
202109 -0.485 115.734 -0.557
202112 -0.540 117.630 -0.611
202203 -0.672 121.301 -0.737
202206 -0.738 125.017 -0.785
202209 -0.818 125.227 -0.869
202212 -0.831 125.222 -0.883
202303 -0.663 127.348 -0.693
202306 -0.517 128.729 -0.534
202309 -0.515 129.860 -0.528
202312 -0.211 129.419 -0.217
202403 -0.699 131.776 -0.706
202406 -0.762 132.554 -0.765
202409 -0.676 133.029 -0.676

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Editas Medicine  (FRA:8EM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Editas Medicine Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Editas Medicine Business Description

Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine Headlines

No Headlines